Skip to main content

Goldberg Itzhak's Form 4 filing

Elicio Therapeutics, Inc. (ELTX) · filed Dec 3, 2021

Accession no.
0001601485-21-000079
Filed
Dec 3, 2021
Trade date
Dec 1-3, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions. Open-market sales total $410.1K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Goldberg ItzhakCIK 0001607858Director, Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 1, 2021Common StockSSaleDisposed−38,867$3.54F2−$137,589.181,831,201Direct
Dec 2, 2021Common StockSSaleDisposed−38,800$3.51F3−$136,1881,792,401Direct
Dec 3, 2021Common StockSSaleDisposed−40,215$3.39F4−$136,328.851,752,186Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.31 to $3.79 inclusive.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.36 to $3.64 inclusive.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.29 to $3.50 inclusive.

Referenced by the price of 1 transaction in Table I.

Remarks

Executive Chairman and Chief Scientific Officer

Read the full filing on SEC EDGAR (opens in a new tab)